Search bioRxiv⌕ Search

bioRxiv · 10.1101/2022.04.26.489492

Assessment of Culicidae collection methods for xenomonitoring lymphatic filariasis in malaria co-infection context in Burkina Faso

Abstract

BackgroundEntomological surveillance of lymphatic filariasis (LF) and malaria infections play an important role in the decision-making of national programs, to control or eliminate these both diseases. In order to corroborate infections in the human population, sampling large numbers of mosquitoes is necessary. To overcome this challenge, this study was design to assess the efficiency of four mosquito collection methods for monitoring LF and malaria infections in mosquito population. Methodology/Principle FindingsMosquito collections were performed between August and September 2018 in four villages (Koulpissy, Seiga, and Peribgan, Saptan), distributed in East and South-West health regions of Burkina Faso. Different collection methods were used: Human Landing Catches (HLC) executed indoor and outdoor, Window Exit-Trap, Double Net Trap (DNT) and Pyrethrum Spray Catches (PSC). Molecular analyses were performed to identify Anopheles gambiae s.l. sibling species and to detect Wuchereria bancrofti and Plasmodium falciparum infection in mosquitoes. A total of 3,322 mosquitoes were collected among this, Anopheles gambiaes.l. was the vector caught in largest proportion (63.82%). An. gambiae s.l. sibling species molecular characterization showed that Anopheles gambiae was the dominant specie in all health regions. The Human Landing Catches (indoor and outdoor) collected the highest proportion of mosquitoes (between 61.5%and 82.79%). For sampling vectors infected to W. bancrofti and P. falciparum, PSC, HLC and Window Exit-Trap were been find as the most effective collection methods. Conclusions/SignificanceThis study revealed that HLC indoor and outdoor remained the most effective collection methods. Likewise, the results showed the probability to use Window Exit-Trap and PSC collection methods to sample Anopheles infected and can be useful for xenomonitoring for both LF and malaria. Author summaryIn Burkina Faso the monitoring and evaluation scheme to assess the impact of LF and malaria interventions is only focusing on parasitological tests. While nowadays, the most simple and direct measure of vector borne diseases is xenomonitoring. Thus, in order to confirm both diseases infection rate in the human population, sampling large numbers of mosquitoes is necessary. This study was undertaken in this context to assess the efficiency of four mosquito collection methods for xenomonitoring LF and malaria. Mosquito collections were performed between August and September 2018 in four villages, distributed in East and South-West health regions of Burkina Faso. Human Landing Catches (HLC), Window Exit-Trap, Double Net Trap (DNT) and Pyrethrum Spray Catches (PSC) were evaluated. The results showed that HLC remained the most effective collection method by collecting the highest number of Anopheles (2,388; 71.88% of total). Across the study, mosquito infection rate for Wuchereria bancrofti and Plasmodium falciparum were 0.004 and 0.13 respectively. To collect vectors infected it was found that Window Exit-Trap and PSC were efficiencies. In conclusion, HLC has shown to be appropriate for collect large number of mosquitoes. Likewise, Window Exit-Trap and PSC can be useful for xenomonitoring for both LF and malaria.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Coulibaly, S., Sawadogo, S. P., Nikiema, A. S., Hien, A. S., Bamogo, R., Koala, L., Sangare, I., Bougma, R. W., Koudou, B. B., Fournet, F., Ouedraogo, G. A., Dabire, R. K.. 2022-04-27. Assessment of Culicidae collection methods for xenomonitoring lymphatic filariasis in malaria co-infection context in Burkina Faso. https://doi.org/10.1101/2022.04.26.489492

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Negative association between nodular stromal fibrosis and large lipid droplets in human choroid plexus epithelial cells

Fibrosis is an age-related change within the human choroid plexus that is likely to affect its function negatively. We systematically analyzed nodular stromal fibrosis present in postmortem tissue from a large repository encompassing the human lifespan. Following manual annotation of sampled images from 81 specimens of choroid plexus from the atrium of the lateral ventricle, a deep learning model was trained to assess stages of fibrosis (dense, hyalinized, and mineralized) occurring in papillae across whole slide images of hematoxylin and eosin-stained sections from 204 cases. The percentage of affected papillae and the relative area of fibrosis at all three stages of severity increased with age. Affected papillae were significantly clustered across the choroid plexus, with areas of high and low fibrotic density. Choroid plexus epithelial cells (CPECs) associated with fibrotic papillae were less likely to contain large lipid droplets than were non-fibrotic papillae, as assessed by another deep learning model. Across papillae within a case, the area of each stage of fibrosis was negatively correlated with the prevalence of CPECs containing large lipid droplets. Finally, individuals displaying more nodular fibrosis had significantly fewer CPECs containing large lipid droplets. Thus, age-related nodular stromal fibrosis may negatively impact lipid storage and homeostasis for the choroid plexus and brain.

pathology↗

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (A{beta}), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: A{beta} or tau. However, DMTs that concurrently target both tau and A{beta} are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces A{beta} and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual A{beta} and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

pathology↗